---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-23-001228"
form_type: "8-K"
ticker: "AXIM"
cik: "0001514946"
company_name: "AXIM BIOTECHNOLOGIES, INC."
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:09:49.771215+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AXIM Biotechnologies enters $20M equity purchase agreement with Cross & Company

## Summary
- Equity Purchase Agreement for up to $20M of common stock with an institutional investor (Cross & Company).
- Company may require investor to buy shares in puts of $10k-$250k, subject to volume limits.
- Purchase price set at 87.5% of lowest traded price during a 10-day valuation period after clearing.
- Agreement term up to 3 years; registration statement on Form S-1 required for resale of put shares.
- Issuance capped at 4.99% beneficial ownership; dilution potential from discounted share sales.

## SEC filing metadata
- accession: 0001096906-23-001228
- form_type: 8-K
- ticker: AXIM
- cik: 0001514946
- company_name: AXIM BIOTECHNOLOGIES, INC.
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514946/000109690623001228/0001096906-23-001228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514946/000109690623001228/axim-20230601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-23-001228
- JSON: https://secwatch.observer/filing/0001096906-23-001228.json
- Plain text: https://secwatch.observer/filing/0001096906-23-001228.txt

## Key facts
- Material Agreements
  AXIM BIOTECHNOLOGIES, INC. entered into Equity Purchase Agreement with an institutional accredited investor (the "Investor") valued at up to $20,000,000 (effective 2023-06-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional accredited investor (the "Investor")
  - Value: up to $20,000,000
  - Effective: 2023-06-01
  source text: On June 1, 2023, AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), entered into an Equity Purchase Agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Investor”), pursuant to which the Investor committed to purchase up to $20,000,000 of the Company’s common stock (the “Financing”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1514946/000109690623001228/0001096906-23-001228-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.